3D Living Tissues

Descrizione del progetto

Un modello 3D biostampato di linfonodo per la scoperta di farmaci

Oltre il 90 % dei farmaci oncologici non superano le prove cliniche. Ciò è imputabile all’impiego di modelli in vitro inaffidabili per la scoperta di farmaci. L’obiettivo del progetto 3DLT, finanziato dall’UE, è portare sul mercato una tecnologia proprietaria di biostampa 3D che adopera cellule umane vive per la produzione di tessuti che rispecchiano fedelmente le loro controparti umane. I ricercatori hanno creato un linfonodo in 3D che funge da piattaforma per la sperimentazione di nuove immunoterapie contro il cancro. Le attività intraprese dal progetto comprendono la valutazione della fattibilità economica relativa all’introduzione del prodotto sul mercato e l’instaurazione dei partenariati industriali e commerciali necessari a raggiungere l’obiettivo prefissato.

Obiettivo

Prometheus S.r.l. develops and markets 3D human like tissues for regenerative medicine and pharmacological tests. A proprietary 3D Bioprinting Technology enables Prometheus to make use of human living cells as ink, to building up 3D tissues equal for structure and features to the human ones. The human living cells are printed by a strictly controlled process with high resolution, remaining alive during the entire printing process and for a long time beyond. The cutting edge new tissues satisfy the requests of pharma/cosmetic companies to reduce R&D expenditures and times for new products commercialization. Prometheus will go-to-market in Jan 2019 with its 1st product: Ematik, for wounds care. In this framework, Prometheus is undertaking a new business opportunity: a 3D Lymph Node (3DLN) for the testing of new immunotherapies against cancer. The 96% of oncological drugs efficient/safety in preclinical tests, fails human clinical trials, with a 2,5Bln$ expenditure/drug. This high failure rate is due to in vitro tests performed with current unreliable tissues: uncomplete, with different cell composition and compartmentalization respect to the corresponding human once. Contrary, Prometheus’ 3D Lymph Node is equal to the human one for composition, structure and functionality, providing more predictive data. Each company tests 80 new molecules/year and spends ≈4 Mln$ for in vitro tests, excluding animal testing (≈4 Mln$). Market of products for immuneonco testing is estimated in 2Bln€. According to key topics, all potential EU customers yearn to find on the market, asap, at any price, a 3D Lymph Node as the one of Prometheus, whose features allow to rapidly acquire a 4% EU market share in 5 years (40Mln€). During the feasibility study we will assess 3DLN project economic feasibility, we will connect with potential customers, estimating deeply market share, defining a revenue forecast, connecting with industrial and commercial partners, define also an IP strategy.

Campo scientifico

Programma(i)

Argomento(i)

EIC-SMEInst-2018-2020 - SME instrument

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-1

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

PROMETHEUS S.R.L.

Contribution nette de l'UE

€ 50 000,00

Indirizzo

Via trento 30
43122 Parma
Italia

PMI

Sì

Regione

Nord-Est Emilia-Romagna Parma

Tipo di attività

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Collegamenti

Contatta l’organizzazione

Partecipazione a programmi di R&I dell'UE

Rete di collaborazione HORIZON

Altri finanziamenti

€ 21 429,00